Though analysts seemed uncertain in February about the commercial future despite favorable phase III data, they came away upbeat from a meeting last week with Trevena Inc. about injectable Olinvo (oliceridine) for moderate to severe acute pain. H.C. Wainwright's Ed Arce said his firm believes the company "has set its eyes on a realistic and promising target market" for the opioid receptor mu agonist, though Wall Street hardly seemed of that opinion earlier in the year.
HONG KONG – In a study led by Australian scientists at University of New South Wales (UNSW), introducing a beneficial natural mutation into blood cells using gene-editing was shown to stimulate production of fetal hemoglobin (Hb), a finding that could lead to a cure for blood diseases.
HONG KONG – Aware of the challenges that lie ahead in China and the need for further investment to expand, drug, device and medical products distributor Cardinal Health may be looking for ways to divest some of its operations announcing that it has "begun to explore strategic alternatives to support its next stage of growth."
HONG KONG – With increasing demand for drugs targeting chronic diseases in China, investment from multinational pharma giants is set to rise, leading to possible benefits for local firms as well. Much of the focus is likely to be on cancer.
Scientists have a limited understanding of neurodegenerative disease processes, particularly those that occur at a molecular level. That makes it very difficult to develop effective drugs to treat disorders such as Alzheimer's disease and multiple sclerosis.
Samumed Inc., of San Diego, disclosed the successful completion of a phase I trial in healthy subjects for its potential treatment of chronic tendinopathy. A detailed analysis, including safety and pharmacokinetic results, will be presented at a future medical conference.
Dompé International SA, of Milan, said the European Commission granted marketing authorization of cenegermin eye drops to treat moderate to severe neurotrophic keratitis, becoming the first approved drug in the EU to treat the rare eye disease, which can cause vision loss.
Vanc Pharmaceuticals Inc., of Vancouver, British Columbia, said it is conducting a non-brokered private placement of up to 10 million units of the company at C$0.15 per unit for gross proceeds of up to C$1.5 million (US$1.2 million).
Merck & Co. Inc. took cardiovascular disease (CVD) experts – and, perhaps, some of its own decision-makers – by surprise last month when it disclosed that the REVEAL (Randomized EValuation of the Effects of Anacetrapib through Lipid modification) outcomes study of its cholesteryl ester transfer protein (CETP) inhibitor, anacetrapib, met its primary endpoint by reducing major coronary events (defined as the composite of coronary death, myocardial infarction and coronary revascularization) compared to placebo in patients at risk for cardiac events who were already receiving a regimen to lower low-density lipoprotein, or LDL.
RSS